SKIN vs. SIBN, EMBC, IRMD, CBLL, BBNX, AVNS, BFLY, KIDS, RXST, and BVS
Should you be buying Beauty Health stock or one of its competitors? The main competitors of Beauty Health include SI-BONE (SIBN), Embecta (EMBC), Iradimed (IRMD), CeriBell (CBLL), Beta Bionics (BBNX), Avanos Medical (AVNS), Butterfly Network (BFLY), OrthoPediatrics (KIDS), RxSight (RXST), and Bioventus (BVS). These companies are all part of the "medical equipment" industry.
Beauty Health vs.
Beauty Health (NASDAQ:SKIN) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
93.3% of Beauty Health shares are owned by institutional investors. Comparatively, 98.1% of SI-BONE shares are owned by institutional investors. 41.0% of Beauty Health shares are owned by company insiders. Comparatively, 4.0% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
SI-BONE has lower revenue, but higher earnings than Beauty Health. SI-BONE is trading at a lower price-to-earnings ratio than Beauty Health, indicating that it is currently the more affordable of the two stocks.
SI-BONE received 135 more outperform votes than Beauty Health when rated by MarketBeat users. Likewise, 69.17% of users gave SI-BONE an outperform vote while only 44.94% of users gave Beauty Health an outperform vote.
In the previous week, Beauty Health had 8 more articles in the media than SI-BONE. MarketBeat recorded 22 mentions for Beauty Health and 14 mentions for SI-BONE. Beauty Health's average media sentiment score of 1.00 beat SI-BONE's score of 0.46 indicating that Beauty Health is being referred to more favorably in the media.
Beauty Health has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Beauty Health has a net margin of -8.11% compared to SI-BONE's net margin of -23.82%. SI-BONE's return on equity of -22.51% beat Beauty Health's return on equity.
Beauty Health currently has a consensus target price of $1.42, indicating a potential downside of 12.01%. SI-BONE has a consensus target price of $22.50, indicating a potential upside of 22.42%. Given SI-BONE's stronger consensus rating and higher possible upside, analysts clearly believe SI-BONE is more favorable than Beauty Health.
Summary
Beauty Health and SI-BONE tied by winning 9 of the 18 factors compared between the two stocks.
Get Beauty Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKIN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beauty Health Competitors List
Related Companies and Tools
This page (NASDAQ:SKIN) was last updated on 5/24/2025 by MarketBeat.com Staff
Buy SKIN Stock Free SKIN Stock Alerts